
Medivir Q4 2024 - Phase IIb Trial Design Set

Redeye comments on Medivir's Q4 report of 2024. In the quarter, the phase IIa study of fostrox was completed. In the conference call, new information about the planned phase IIb study, FOcuS-2, was presented. Furthermore, we present a new valuation model with a new base case.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Medivir Q4 2024 - Phase IIb Trial Design Set](#)